Navigation Links
CeloNova BioSciences Announces World's First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
Date:9/8/2007

ATLANTA, Sept. 8 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), a leading developer of innovative medical devices, today unveiled the world's first fully color-coded line of embolic particles, Embozene(TM) Color-Advanced Microspheres, at the annual meeting of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) in Athens, Greece.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070908/CLSA008 )

Embolic microspheres are used to treat liver cancer, fibroids, and other hypervascularized tumors. "With the release of Color-Advanced Microspheres, interventional radiologists now have available a highly biocompatible, precisely calibrated embolic particle that offers the unique safety and convenience advantages of being color coded by microsphere size. Nothing else on the embolic market offers such a compelling package of superior clinical performance combined with total ease-of-use for the physician," stated CeloNova President and Chief Executive Officer Thomas A. Gordy.

Ranging in size from 40 microns (approximately the diameter of a human hair) to 900 microns and based on the company's already well-received opaque microspherical product, Embozene(TM) Color-Advanced Microspheres now offer the additional benefit of enhanced visibility and instant, effortless identification of microsphere size by color. This means:

-- Immediate visual confirmation that the microspheres are properly mixed

before injection;

-- Reduced risk of cross-contamination during the procedure;

-- A reduced risk of injecting too many or too few microspheres because

they are clearly visible;

-- No more waste due to uncertainty when a physician is operating with

multiple microsphere sizes.

Gordy continued: "From the beginning, CeloNova has operated on the principle that our products would be designed with class-leading clinical outcomes and the real-world needs of physicians and operating room staff in mind. Embozene(TM) Color-Advanced Microspheres represent the embodiment of that philosophy in action; color-coding improves patient safety while simplifying the job of those performing the procedure."

Embozene(TM) Color-Advanced Microspheres are the next evolution in an embolic platform and are available either in vials or pre-filled syringes depending on physician preference.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, and possesses both anti-bacterial and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes its Embozene(TM) Microspheres, used to treat arteriovenous malformations, hypervascularized tumors, uterine fibroids and hepatocellular carcinoma. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):